European Journal of Molecular & Clinical Medicine

Background: Common fungal infections like dermatophytosis are brought on by Trichophyton, Epidermophyton, and Microsporum species. All patients with dermatophytosis should get a combination of systemic and topical antifungal medication, with the exception of those who have localised naive tinea. Study participants took oral terbinafine and itraconazole to see how well they worked together against superficial dermatophytosis.
Materials and Methods: For this randomised clinical trial, 50 people with superficial dermatophytosis were divided into two groups. The study was conducted in the Department of Dermatology's Outpatient Department from December 2021 to May 2022. Treatment in Group I consisted of four weeks on Terbinafine 250 mg OD and 200 mg OD itraconazole, whereas in Group II, just Terbinafine 250 mg OD was given. As a result, the patients were seen every two weeks and given the necessary diagnostics. The statistical analysis was performed using SPSS version 16.0, the Statistical Package for the Social Sciences.
Results: Itraconazole containing group reported a better clinical cure rate than the griseofulvin containing group (p<0.05). Neither of the combination showed effectiveness against tinea infections pre-treated with topical steroid containing formulations.
Conclusion: When terbinafine and itraconazole are combined, a greater clinical cure rate is achieved than when terbinafine is used alone.

Background: Superficial dermatophytosis affecting hair, skin and nail are common public health problem in India, because of the tropical climate with heat and humidity. The present study was conducted to assess efficacy of oral terbinafine versus itraconazole in treatment of dermatophytic infection of skin.
Materials & Methods: The patients were randomly divided into two groups to receive a daily dose of terbinafine 500 mg daily for 4 weeks (Group I) or 200 mg of itraconazole for 4 weeks daily (Group II). Patients were followed up after 2 weeks and 4 weeks of the study period. At each visit, clinical response was noted including pruritus, erythema, and scaling. All analysis was done SPSS version 21.0 (IBM Corp., Armonk, NY).
Results: A total of 100 patient were randomly divided into two groups to receive a daily dose of terbinafine 500 mg daily for 4 weeks (Group II) or 200 mg of itraconazole for 4 weeks daily (Group I). At baseline in group I erythema was severe in maximum patients, scaling, pruritus was moderate in maximum patients. At 2^nd week in group I erythema, pruritus was moderate in maximum patients, scaling was mild in maximum patients. At 4^th week in group I erythema, pruritus was mild in maximum patients, scaling was absent in maximum patients. At baselie in group II erythema was equally moderate and severe in maximum patients, scaling, pruritus was moderate in maximum patients. At 2^nd week in group II erythema was moderate in maximum patients, scaling and pruritus was mild in maximum patients. At 4^th week in group I erythema, pruritus was mild in maximum patients, scaling was absent in maximum patients.
Conclusion: The present study concluded that Itraconazole has higher clinical and mycological cure rates as compared to terbinafine. erythema and scaling was absent in more patients in group I than group II.

Aim: To analyse clinico-mycological and therapeutic study of recurrent dermatophytic
infections and determining the right dose and duration of systemic antifungals.
Material and methods: This randomized controlled trial was conducted at the
department of DVL, Acharya Shri Chander College of Medical Sciences, Jammu from
January 2021 - May 2021 among 90 patients with superficial cutaneous fungal infection
coming to the dermatology OPD. Selected 90 patients were assigned to a trial group and
given the standard dose of the drug i.e. Tab. Itraconazole (100mg OD), Tab.
Griseofulvin (250mg BD) and Tab. Terbinafine (250mg OD). Evaluation was done by
clinical assessment in terms of clinical score. The clinical signs and symptoms assessed
were scaling, erythema, and pruritus.
Results: Tinea corporis was the principal dermatophytic lesion accounted for 93.33% of
the study subjects. Pruritus, Erythema, scaling and total scores reduced significantly in
all the drugs i.e. Griseofulvin, Itraconazole and Terbinafine. However reduction was
reported more in Itraconazole drug in our study. Complete clinical cure was reported in
3.33%, 70% and 26.67% of the subjects in Itraconazole drug at 1st visit (3w), 2nd visit
(6w) and 3rd visit (9w) respectively. No cure was reported in Griseofulvin and
Terbinafine drug at 1st visit (3w). 23.33%, 76.67% and 6.67%, 43.33% of the subjects
in Griseofulvin and Terbinafine drug were completely cured at 2nd visit (6w) and 3rd
visit (9w) respectively.
Conclusion: Itraconazole was found to be the best drug for the treatment of
dermatophytes among the tested antifungals.

Background:Dermatophytosis is a common skin diseasein Egypt. It iscaused by
keratinophilic fungi. Tinea become chronic, recurrent and resistant to traditional
therapies. Isotretinoin is a good adjuvant to systemic antifungal in chronic
dermatophytosis due to its keratolytic effect.
Aim: This is a prospective study to assess the effectiveness of combined oral
itraconazole/isotretinoin therapyin the treatment of chronic and recalcitrant
dermatophytosis.
Patients and Methods:A total of 30 patients with chronic and/or recalcitrant
dermatophytosis were included. Potassium hydroxide microscopy was performed.All
the patients received combined oral itraconazole/isotretinoin therapy;Itraconazole
200 mg twice daily with adjuvant isotretinoin20 mg dailyfor 6 weeks. The patients
were followed up to 6 monthsfor signs of recurrence.
Results:Mycological cure was observed in83.3% andcomplete cureoccurred in 70%
of the patients.
Conclusions: Combined oral itraconazole/isotretinoin therapycould be an effective
treatment in recalcitrant dermatophytosis.